Esperion Therapeutics
ESPR
ESPR
150 hedge funds and large institutions have $1.21B invested in Esperion Therapeutics in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.7% less ownership
Funds ownership: 94.73% → 94.04% (-0.7%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
46% less call options, than puts
Call options by funds: $23M | Put options by funds: $42.8M
Holders
150
Holding in Top 10
6
Calls
$23M
Puts
$42.8M
Top Buyers
| 1 | +$86.7M | |
| 2 | +$29.3M | |
| 3 | +$16.8M | |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$12.8M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$12.6M |
Top Sellers
| 1 | -$33.9M | |
| 2 | -$25.1M | |
| 3 | -$12.3M | |
| 4 |
PC
Paulson & Co
New York
|
-$9.74M |
| 5 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$9.12M |